GIKLY - Grifols launches hepatitis B treatment HyperHEP B

Grifols ([[GIKLY]]) announces that it has begun commercializing HyperHEP B, a new formulation of its hepatitis B immune globulin for hepatitis B postexposure prophylaxis.The new formulation, which was approved by the U.S. FDA in December 2020, uses a unique caprylate chromatography process, which significantly reduces procoagulant activity and IgG aggregates.It is estimated that between 800K and 1.4M people in the U.S. are currently infected with hepatitis B.Grifols had announced the start of a clinical trial to evaluate the safety and efficacy of a new COVID-19 drug, containing anti-SARS-CoV-2 polyclonal antibodies from plasma donors who have recovered from the disease, in January.

For further details see:

Grifols launches hepatitis B treatment HyperHEP B